UAMS BioVentures Featured in Arkansas Business

BioVentures director Nancy Gray told AB's Sean Beherec that BioVentures startups, many of which are IA client firms, are growing and revenues are up.

Examples of IA firms coming out of BioVentures include RxResults, Angel Eye and InterveXion Therapeutics. (More on Angel Eye recently from AB here.)

An excerpt from this week's BioVentures piece:

The University of Arkansas for Medical Sciences BioVentures was launched more than a decade ago with that concept in mind and seeks to combine research at UAMS with entrepreneurship, technology licensing and economic development. BioVentures has since spun off 22 companies using technologies developed at the campus.

Nancy Gray, who became director for the program on Feb. 2, has worked in the biomedical industry for more than 30 years, most recently at the Southern Research Institute in Birmingham, Alabama.

BioVentures receives revenue from intellectual property developed at the university and licensed through BioVentures, and Gray said the university is reporting yearly gains. This fiscal year, which will end next month, BioVentures expects to collect more than $2 million in revenue from 18 license agreements, which includes seven that are now spinoff companies.

That revenue is nearly double the $1.1 million collected in fiscal 2013 and represents a steady increase from the $735,000 in revenue collected in fiscal 2011.